Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06400121
Status:
RECRUITING
Last Update Posted:
2024-06-05
First Post:
2024-05-01
Brief Title:
Apimostinel Automated Neurocognitive Training for Depression
Sponsor:
Rebecca Price
Organization:
University of Pittsburgh
Study Overview
Official Title:
Phase 2 Randomized Double-Blind Placebo-Controlled Single Intravenous Dose Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects With Major Depressive Disorder
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns Cognitive Training CT is a digital intervention that has shown promise in extending the durability of another similar drug ketamine This randomized controlled trial will test the efficacy and safety of apimostinel vs placebo for the acute treatment of depression and will test the potential of CT to enhance andor extend the durability of apimostinels antidepressant effect
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None